



Shareholder Memo

Accounting year: From April 1 through March 31 of the following year

Annual meeting of shareholders:

June

Record date: Year-end dividend, March 31

Interim dividend, September 30

Method of official announcement:

We will post electronic public announcements to the following URL:

<http://www.moritex.co.jp>

*1 In case we are unable to post an announcement via electronic public announcement due to unavoidable circumstances, we will post an announcement in the Nihon Keizai Shimbun.

*2 In lieu of official announcement of settlement of accounts, we disclose our balance sheet and income statement via EDINET (Electronic disclosure system regarding disclosure documents such as financial statements based on the Securities and Exchange Law).

Transfer of shares (Manager of list of shareholders):

3-33-1, Shiba, Minato-ku, Tokyo

The Chuo Mitsui Trust and Banking Company, Main Branch

Stock handling office (Mailing address, Telephone inquiry contact):

2-8-4, Izumi, Suginami-ku, Tokyo 168-0063, Japan

The Chuo Mitsui Trust and Banking Company, Securities Agent Department

TEL. 0120-78-2031 (toll-free)

Agent for stock handling office:

Nationwide branches of Chuo Mitsui Trust and Banking

Head office and nationwide branches of Japan Securities Agents, Ltd.

36th Business Report

April 1, 2007 through March 31, 2008



Moritex Head Office Bldg., 3-1-14, Jingu-Mae, Shibuya-ku, Tokyo 150-0001, Japan
TEL. 03-3401-9711 (Main phone number) Website: <http://www.moritex.co.jp>



Interview with the President	1~3
36th Period Financial Overview	4
· Overview of Settlement of Accounts	
(Consolidated/Non-consolidated)	4
· Constitution of Sales by Business	
(Consolidated)	4
Overview of Sales	
Optical Application Equipment Business	5
Machine Vision System/	
Image Equipment-related/	
Optical Communications-related Equipment/	
Test/Measurement Equipment	
Functional Materials Business	6
Bio-related Business	6
Other Businesses	6
Financial Statements (Consolidated)	
Balance Sheet (Abstract)	7
Income Statement (Abstract)	7
Statement on Changes in Shareholders' Equity, etc.	7
Cash Flow Statement (Abstract)	8
Major Subsidiaries and Affiliates	8
Financial Statement (Non-consolidated)	
Balance Sheet (Abstract)	9
Income Statement (Abstract)	9
Statement on Changes in Shareholders' Equity, etc.	
Condition of Shares	10
Share Distribution Status	10
Shift in Business Results	10
(Consolidated) in Graphs	11
Topics	12
Corporate Profile	13~14
Corporate profile/Offices/	
Major Subsidiaries and Affiliates	
Shareholder Memo	15



36th Business Report

Interview with the President

On March 16, 2008, Shuitsu Nishina assumed the post of President and CEO. We have asked the new president about the future of Moritex.



President and CEO
Shuitsu Nishina

Q1. Talk to us about your aspirations as the new president.

It has been 24 years since I joined Moritex, but to be honest, I never thought I would assume the post of president. However, I have decided to assume the post of president since now is a tough time for our Company.

Various things have occurred up to this point, but as the President and CEO, I will strive to seek for harmony within and outside the company, while striving to enhance business performance and strive to the best of my ability to enhance corporate value in order to respond to the expectations of all stakeholders.

Q2. Tell us about the business results for this term.

Our Company Group is implementing the medium-term management plan "Global 10" covering the period from April 2007 through March 2010. We had planned to promote various measures during this term as the initial year, but were unable to make much progress in the plan due to conflict arising over the Company and other factors.

As a result, the Company Group's business results for this term (April 1, 2007 through March 31, 2008) showed a slight decrease in sales from the previous year. Profit increased from the previous year, thanks to the success of company-wide cost reduction efforts and a drastic decline in costs related to the beads shop business terminated at the end of the previous term. Therefore, this term resulted in a sales decline and profit increase.

Amid such conditions, the Company formed a business alliance with SCHOTT of Germany and established a subsidiary in Singapore and launched the German Office of Moritex EUROPE, making a major strategic move toward future overseas development.

As my job, I would like to nurture the strategic moves taken in the past toward promoting globalization into full growth.

Q3. Please tell us about the recent business environment and the forecast for the 37th Period (Year to March 2009).

A tough management environment is expected to continue, with the decline in DRAM prices, etc. pressuring respective semiconductor manufacturers to curb capital investment in the semiconductor manufacturing device industry, the major sale destination of Moritex Group.

Amid such an environment, Moritex Group's Machine Vision System Products Division seeks to make up for setbacks in the semiconductor manufacturing device industry by strengthening sales activities targeting the liquid crystal manufacturing device industry, which is expected to see an upturn in business. In response to growing demand for parts such as lenses for FTTH (Fiber to the Home), the Optical Communications-related Equipment Division will implement capital investment, which is slated to start full-fledged operations in the second half of the fiscal year.

As for the Bio-related Business, the completion of the PGx (pharmacogenomic) Research Center's GLP (Good Laboratory Practice) certification has enabled the full-fledged supply of PGx test services of even higher reliability in the second fiscal half. We expect sales to expand in this area as well.

Through these measures, we plan to minimize the impact of restraints in capital investment in the semiconductor industry and secure consolidated sales of 16 billion yen. We expect profit to increase, with the absence of extraordinary costs related to the general meeting of shareholders as well as the impacts of improved business income and expenditure following the launch of full-fledged operations of optical parts manufacturing facilities and the PGx Research Center in the second half of the fiscal year, intensified selection and concentration in the R&D field, intensified reform activities of employees' mindset toward focus on profit and loss, etc. We aim for operating profit of 700 million yen, ordinary profit of 700 million yen and current net income of 580 million yen on a consolidated basis.

Q4. What is your focus when facilitating management strategies?

When I assumed the post of president, I sent out a message to the employees. I advocated the following two points. One is to have close communication within the company.

I believe that employee motivation is what creates corporate value. When a company has such high motivation that all its employees feel eager to go to work when they wake up in the morning, the proposal to a client alone is different. Employees would be able to make proactive proposals that increase customer satisfaction, thus leading to enhancement of corporate value. So in order to heighten motivation, I made a request to the employees to realize close communication within the company.

Since Moritex has clients in a relatively large number of industries despite its company size, I believe close communication within the company would enable discovery of new business chances that have been overlooked in the past. I also believe that communication is essential in developing an environment in which employees can experience fulfillment through their jobs. I sent out a message that the management team would make efforts to realize such work environment and that I would like all employees to cooperate.

I mapped out the policy of "focusing on profit" as the second policy.

As an R&D-type company, Moritex has been engaged in R&D activities in many cutting-edge fields. Although R&D activities have impact in terms of heightening the Company's technological capabilities, many cases extend over a long period of time, having the adverse effect of contributing little to short-term revenue.

Therefore, we mapped out the policy of implementing selection and concentration of R&D activities, daringly narrowing down R&D that requires time before commercialization and focusing investment of management resources on specific R&D activities that are expected to be commercialized at an early date. In the future, we will conduct marketing activities for investment in commercialization in an even more scrupulous manner than before. On the other hand, we believe R&D activities will speed up.

Q5. Finally, what is your message to shareholders?

We apologize for causing great worries among our shareholders last year. Starting this term, I would like to lead the management toward maximization of corporate value in order to respond to the mandate of our shareholders under a new management setup.

The basic management policy is to expand business as a manufacturer by facilitating the development of high-value-added products optimizing the Company's technical capabilities and supplying the market with products that respond to users' needs. We will also facilitate development of products of high novelty as an R&D company, but as for R&D investment, we will strictly estimate the possibility of commercialization, strive to speed up commercialization by narrowing down the direction of development, and adopt a management style that focuses on securing profits more than ever before.

We will appreciate further help and encouragement from our shareholders in the years to come.


Overview of Settlement of Accounts

(Unit: fractions of less than a million yen are omitted)

	Consolidated		Non-consolidated	
	Current term (36th term)	Previous term	Current term (36th term)	Previous term
Sales	16,121	16,510	14,004	13,755
Operating profit	320	154	149	△ 21
Ordinary profit	360	358	241	192
Current net income	184	△ 1,495	5	△ 1,662
Current net earnings per share (yen)	13.34	△ 109.21	0.41	△ 121.19
Total assets	15,023	15,072	14,405	14,320
Net assets	7,560	7,680	7,354	7,559
Net assets per share (yen)	540.18	550.87	529.26	546.78
Rate of return on equity	2.4	△ 18.1	0.1	△ 20.0

Constitution of Sales by Business (Consolidated)

	Machine vision system	Image equipment-related	Optical communication-related equipment	Test/Measurement equipment	Functional materials	Bio-related	Other
36th Term (Year to March 2008)	10,580	1,898	676	132	1,679	1,043	108
35th Term (Year to March 2007)	10,281	2,225	591	44	1,709	1,057	600
34th Term (Year to March 2006)	9,027	1,912	586	65	1,471	963	738



Optical Application Equipment Business

Machine Vision System

The Machine Vision System Division sells lens, light source and optical fiber light guide, etc. as FA (factory automation) imaging/image processing systems to mainly the semiconductor industry and LCD manufacturing device industry, either as components or as modules combining these.

Demand from the semiconductor manufacturing device industry was lackluster this term, as semiconductor manufacturers curbed capital spending due to the impact of prolonged weakness in DRAM prices in the semiconductor industry. On the other hand, demand from an electronic component mounting device manufacturer was firm, and the LCD manufacturing device industry in the second half of the fiscal year saw recovery in enthusiasm about capital spending that had been restrained thus far.

Particularly because of strong demand from an electronic component mounting device manufacturer, sales increased from the previous term, but operating profit decreased from the previous term because the constitution of sales of products with low profit margins increased.

As a result, sales of the division came to 10,580 million yen, up 2.9% from the previous consolidated accounting year.



Image Equipment-related

Sales related to skin counseling systems for the cosmetics industry decreased from the previous term since product replacement demand from clients in the cosmetics industry declined compared to the previous accounting year. Operating losses decreased compared to the previous term, partly due to the absence of costs for changes in product specifications, which had lowered profit in the previous term.

As for CCD microscopes (Scopeman) for the industrial products arena, the introduction of the new compact product "Scopeman MSX-500Di" into the market was delayed, but sales were hovering at strong levels after the launch. However, operating losses increased from the previous term due to renovation costs, etc. for the technical improvements made to mainstay product "MS-804."

As a result of the above, the division's sales came to 1,898 million yen, down 14.7% from the previous year.



Optical Communications-related Equipment

In the optical communications market, there are signs of recovery in demand for components such as lenses for FTTH (Fiber to the Home) purposes. In terms of investments on module-manufacturing facilities, etc., there is slight renewal demand. As a result, the division's sales came to 676 million yen, up 14.5% from the previous year.

Test/Measurement Equipment


The Test/Measurement Equipment Division applies the optical technology of the Company and handles sales of products such as "ellipsometers," devices that evaluate thin films, the "Wave checker," a system to inspect the spectroscopic characterization of optical components and "high-speed 3D image processing inspection systems" that conduct inline configuration tests. This accounting period, the Company has focused on selling "LayScan," a liquid crystal molecular orientation film test equipment which it started selling in the previous term, and "IRise @ 700 IR Vision System," an infrared transmission inspection system for silicon devices it started selling.

As a result, the division's sales came to 132 million yen, up 196.6% from the previous year.

Functional Materials Business

In terms of high-purity quartz for the optical communications-related industry handled under the functional materials business, FTTH (Fiber to the Home) demand carried over strength from the previous term. Further, sales hovered at previous year's levels for various medical-use tubes, highly functional Teflon stickers (Bal seals) for the bio/medical equipment arena and standard particles for the semiconductor industry, but sales declined slightly, due in part to year-on-year decline in sales turnover of dielectric coating used as electromagnetic wave shield material.

As a result, sales for the division came to 1,679 million yen, down 1.8% from the previous year.




Bio-related Business

Sales of devices centered on mainstay product "Purif" series, an automatic refining device, declined compared to strong sales in the previous year, keeping sales hovering at previous year's levels despite the growth in order receipts for the gene manifestation SNPs analysis service.

In terms of profit, operating losses grew as depreciation costs increased along with the implementation of investment toward obtaining Pharmacogenomics (PGx) Research Center's GLP (Good Laboratory Practice) this consolidated accounting year.

As a result of the above, the division's sales came to 1,043 million yen, down 1.4% from the previous year.



Other Businesses

Sales largely declined compared to the previous term following the termination of the beads shop business geared toward consumers as of the end of the previous term. Currently, the main constituent of sales are services provided by consolidated subsidiaries Moritex Hong Kong Co., Ltd. and KOLC Inc.

As a result, the division's sales came to 108 million yen, down 81.9% from the previous year.

Balance Sheet (Abstract)

(Unit: thousand yen)

Account	By term	Current term (as of March 31, 2008)	Previous term (as of March 31, 2007)
Assets			
Liquid assets		8,820,594	8,811,729
Fixed assets		6,203,178	6,261,235
Tangible fixed assets		4,502,431	4,590,701
Intangible fixed assets		162,638	132,701
Investment and other assets		1,538,107	1,537,832
Total assets		15,023,773	15,072,965
Liabilities			
Liquid liabilities		5,288,935	5,167,104
Fixed liabilities		2,174,805	2,225,424
Total liabilities		7,463,741	7,392,529
Net assets			
Shareholders' equity		7,625,543	7,579,265
Capital		3,320,241	3,320,170
Capital surplus		3,387,658	3,387,658
Retained earning		917,895	871,688
Treasury stock		△ 252	△ 252
Valuation/Conversion Adjustment, etc.			
Variance from valuation of other securities		9,315	36,253
Gain/loss on deferred hedge		△ 38,462	6,703
Exchange rate conversion adjustment		△ 90,275	△ 6,576
Total valuation/conversion adjustment		△ 119,422	36,380
Minority interest		53,911	64,790
Total net assets		7,560,031	7,680,436
Total liabilities and net assets		15,023,773	15,072,965

*Fractions of less than thousand yen are omitted

Income Statement (Abstract)

(Unit: thousand yen)

Account	By term	Current term (From April 1, 2007 through March 31, 2008)	Previous term (From April 1, 2006 through March 31, 2007)
Sales		16,121,037	16,510,768
Cost of sales		11,496,076	11,769,240
Gross profit on sales		4,624,961	4,741,528
Selling and general administrative expenses		4,304,632	4,587,316
Operating profit		320,328	154,211
Non-operating revenue		150,488	269,868
Non-operating cost		110,231	65,591
Ordinary profit		360,585	358,488
Extraordinary loss		181,141	1,752,007
Loss on sales of fixed assets		6,997	-
Loss on retirement of fixed assets		87,126	68,755
Valuation losses on investment securities		87,017	54,631
Losses on business reorganization		-	1,098,016
Losses from disposal of inventory assets		-	465,303
Losses due to impairment		-	65,301
Current net income or loss before taxes and others (△)		179,443	△ 1,393,518
Income tax, resident tax and enterprise tax		76,263	68,971
Income taxes – deferred		△ 79,679	19,519
Minority interests in subsidiary or loss (△)		△ 1,669	13,605
Current net income or loss (△)		184,528	△ 1,495,615

*Fractions of less than thousand yen are omitted

Cash Flow Statement (Abstract)

(Unit: thousand yen)

Account	By term	Current term (From April 1, 2007 through March 31, 2008)	Previous term (From April 1, 2006 through March 31, 2007)
		Amount	Amount
Cash flow from operating activities		1,454,727	627,918
Cash flow from investment activities		△ 667,411	△ 695,415
Cash flow from financial activities		△ 336,346	△ 179,001
Exchange difference of cash and cash equivalents		△ 19,751	5,369
Increase/Decrease in cash and cash equivalents		431,218	△ 241,129
Outstanding balance of cash and cash equivalents at beginning of FY		1,729,984	1,975,026
Decrease in cash and cash equivalents due to exclusion from consolidated accounting		-	△ 3,913
Outstanding balance of cash and cash equivalents at end of FY		2,161,202	1,729,984

*Fractions of less than thousand yen are omitted

Statement on Changes in Shareholders' Equity, etc.

(Unit: thousand yen)

	Shareholders' equity				
	Capital	Capital surplus	Retained earning	Treasury stock	Total shareholders' equity
Balance as of March 31, 2007 (thousand yen)	3,320,170	3,387,658	871,688	△ 252	7,579,265
Changes during consolidated accounting period					
Issuance of new shares due to exercising of share warrant	71				71
Dividend of surplus			△ 138,322		△ 138,322
Current net profits			184,528		184,528
Changes (net change) in items other than shareholders' equity during consolidated accounting period					
Total change during consolidated accounting period (thousand yen)	71	-	46,206	-	46,277
Balance as of March 31, 2008 (thousand yen)	3,320,241	3,387,658	917,895	△ 252	7,625,543


	Valuation/conversion adjustment, etc.				Minority interest	Total net assets
	Valuation adjustment for other securities	Gain/loss on deferred hedge	Exchange rate conversion adjustment	Total of valuation/conversion adjustment		
Balance as of March 31, 2007 (thousand yen)	36,253	6,703	△ 6,576	36,380	64,790	7,680,436
Changes during consolidated accounting period						
Issuance of new shares due to exercising of share warrant						71
Dividend of surplus						△ 138,322
Current net profits						184,528
Changes (net change) in items other than shareholders' equity during consolidated accounting period	△ 26,937	△ 45,166	△ 83,699	△ 155,803	△ 10,878	△ 166,682
Total change during consolidated accounting period (thousand yen)	△ 26,937	△ 45,166	△ 83,699	△ 155,803	△ 10,878	△ 120,404
Balance as of March 31, 2008 (thousand yen)	9,315	△ 38,462	△ 90,275	△ 119,422	53,911	7,560,031

Major Subsidiaries and Affiliates

Company name	Capital (thousand yen)	Voting right ratio	Major business
Moritex U.S.A., Inc.	Thousand USD 700	100.0%	Sales of the Company's products in the U.S. region. Purchasing of the Company's functional products for the U.S. region.
Moritex Europe Ltd.	Thousand GBP 877	100.0%	Sales of the Company's products in the European region 20/Moritex Singapore Pte Ltd.
Moritex Singapore Pte Ltd.	Thousand SGD 1,500	100.0%	Sales and manufacture of the Company's products in the Southeast Asia region
Moritex Sales Corporation	30,000	100.0%	Sales of the Company's products and commodities
KOLC Inc.	30,000	90.0%	Temporary staffing, job placement, nonlife insurance agent, etc.
Moritex Hong Kong Co., Ltd.	Thousand HKD 24,000	87.4%	Manufacture and sales and export/import of Company's products
Moritex Precision Corporation	60,000	33.3%	Manufacture and sales of metal parts and products related to information and telecommunications equipment and OA equipment, and synthetic resin parts and products
Tohoku Moritex Corporation	50,000	30.0%	Sales of the Company's products and commodities in the Tohoku region. Manufacture of multicomponent glass optical fiber and processing of various optical fiber
Sensor Technology Co., Ltd.	45,000	21.0%	Development/manufacture and sales of electronics device applying various CCD cameras and sensors

Status of business combinations

The Company has established Moritex Singapore Pte Ltd. as of late November 2007 with voting ratio of 100.0% for the purpose of expanding sales in the Southeast region.



■ Balance Sheet (Abstract)

(Unit: thousand yen)

Account	By term	Current term (as of March 31, 2008)	Previous term (as of March 31, 2007)
Assets			
Liquid assets		8,081,412	8,051,463
Fixed assets		6,324,019	6,268,627
Tangible fixed assets		3,998,618	4,039,180
Intangible fixed assets		123,868	102,397
Investment and other assets		2,201,532	2,127,049
Total assets		14,405,431	14,320,090
Liabilities			
Liquid liabilities		4,909,258	4,577,147
Fixed liabilities		2,141,735	2,183,856
Total liabilities		7,050,993	6,761,003
Net assets			
Shareholders' equity		7,383,584	7,516,130
Capital		3,320,241	3,320,170
Capital surplus		3,387,658	3,387,658
Retained earning		675,937	808,554
Treasury stock		△ 252	△ 252
Valuation/Conversion Adjustment, etc.			
Variance from valuation of other securities		9,315	36,253
Gain/loss on deferred hedge		△ 38,462	6,703
Total valuation/conversion adjustment		△ 29,146	42,957
Total net assets		7,354,437	7,559,087
Total liabilities and net assets		14,405,431	14,320,090

*Fractions of less than a thousand yen are omitted

■ Income Statement (Abstract)

(Unit: thousand yen)

Account	By term	Current term (From April 1, 2007 through March 31, 2008)	Previous term (From April 1, 2006 through March 31, 2007)
Sales		14,004,417	13,755,451
Cost of sales		10,149,651	9,781,838
Gross profit on sales		3,854,766	3,973,612
Selling and general administrative expenses		3,705,333	3,994,624
Operating profit or operating loss (△)		149,432	△ 21,012
Non-operating revenue		167,571	258,464
Non-operating cost		75,381	44,923
Ordinary profit		241,622	192,528
Extraordinary loss		291,774	1,794,586
Loss on sales of fixed assets		19,008	-
Loss on retirement of fixed assets		86,558	68,180
Valuation losses on investment securities		87,017	54,631
Losses on business reorganization		-	1,141,169
Losses from disposal of inventory assets		-	465,303
Losses due to impairment		-	65,301
Losses on assisting affiliates		99,189	-
Current net loss before taxes and others		△ 50,152	△ 1,602,057
Income tax, resident tax and enterprise tax		26,000	39,787
Income taxes – deferred		△ 81,857	20,581
Current net income or loss (△)		5,705	△ 1,662,426

*Fractions of less than a thousand yen are omitted

■ Statement on Changes in Shareholders' Equity, etc. Current consolidated accounting period (From April 1, 2007 through March 31, 2008) (Unit: thousand yen)

	Shareholders' equity							Treasury stock	Total shareholders' equity
	Capital	Capital surplus		Retained earning					
		Capital reserve	Earned reserve	Special depreciation reserve	Dividend reserve	Separate reserve	Retained earnings carried forward		
Balance as of March 31, 2007 (thousand yen)	3,320,170	3,387,658	73,359	29,427	672,000	1,340,000	△ 1,306,232	△ 252	7,516,130
Changes during accounting period									
Issuance of new shares due to exercising of share warrant	71								71
Reversal of special depreciation reserve				△ 12,654					12,654
Reversal of dividend reserve					△ 72,000				72,000
Reversal of separate reserve						△ 1,340,000			1,340,000
Dividend of surplus							△ 138,322		△ 138,322
Current net profits							5,705		5,705
Changes (net change) in items other than shareholders' equity during consolidated accounting period									
Total change during accounting period (thousand yen)	71	-	-	△ 12,654	△ 72,000	△ 1,340,000	1,292,037	-	△ 132,545
Balance as of March 31, 2008 (thousand yen)	3,320,241	3,387,658	73,359	16,772	600,000	-	△ 14,194	△ 252	7,383,584

	Valuation/conversion adjustment, etc.			Total net assets
	Valuation adjustment for other securities	Gain/loss on deferred hedge	Total of valuation/conversion adjustment	
Balance as of March 31, 2007 (thousand yen)	36,253	6,703	42,957	7,559,087
Changes during accounting period				
Issuance of new shares due to exercising of share warrant				71
Reversal of special depreciation reserve				
Reversal of dividend reserve				
Reversal of separate reserve				
Dividend of surplus				△ 138,322
Current net profits				5,705
Changes (net change) in items other than shareholders' equity during consolidated accounting period	△ 26,937	△ 45,166	△ 72,103	△ 72,103
Total change during accounting period (thousand yen)	△ 26,397	△ 45,166	△ 72,103	△ 204,649
Balance as of March 31, 2008 (thousand yen)	9,315	△ 38,462	△ 29,146	7,354,437


Condition of Shares

Number of shares that can be issued: 30,000,000 shares
 Total number of outstanding shares: 13,895,928 shares
 Number of shareholders: 9,022 shareholders


Major shareholders (Top 10)

Major shareholder	Number of shares held	Investment ratio
IDEC Corporation	1,619,700 shares	11.7 %
Yukoh Morito	1,030,060 shares	7.4 %
Japan Trustee Service Bank, Ltd. (as Trustee)	503,100 shares	3.6 %
The Master Trust Bank of Japan, Ltd. (as Trustee)	227,200 shares	1.6 %
Moritex Employee Holding Group	206,300 shares	1.5 %
The Dai-ichi Mutual Life Insurance Company	180,600 shares	1.3 %
Mizuho Corporate Bank, Ltd.	180,000 shares	1.3 %
Shineikai (holding group at client company)	171,300 shares	1.2 %
Trust & Custody Services Bank, Ltd.	146,700 shares	1.1 %
Deutsche Bank AG Frankfurt	144,400 shares	1.0 %


Share Distribution Results




Sales
(million yen)




Ordinary Profit
(million yen)




Current Net Income
(million yen)




Current Net Earnings per Share
(yen)



Net Assets
(million yen)



Net Assets per Share
(million yen)



Moritex Starts Full-fledged Sales of Products by Global Special Glass Maker SCHOTT AG

Moritex started full-fledged sales of various light source devices manufactured by global high-performance special glass manufacturer SCHOTT AG of Germany.

SCHOTT, which is owned by Carl Zeiss Foundation, is a highly skilled international corporate group that develops and manufactures special materials, parts and systems used in consumer electronics products, optics and optoelectronics, pharmaceutical and solar energy divisions.

On the other hand, Moritex has been critically acclaimed by the market for selling "machine vision systems" that combine optical components such as light source devices, optical fiber light guides, machine microlenses (MML), LED illumination devices and CCD cameras geared toward semiconductor manufacturing devices and LCD manufacturing devices, electronic component mounting devices and other image processing-related arenas.

Moritex and SCHOTT concluded a "Memorandum for Business Alliance" on June 13, 2007 and have strived for progress in the alliance. At "The 18th FINETECH Japan," the world's largest exhibition in the FPD industry, held at Tokyo Big Sight from April 16 to 18, 2008, we installed a "SCHOTT Section" in the Moritex exhibition booth and introduced light source devices (150W Halogen Feedback Light Source DCR IV / LED Light Source Box LLS / LED Line Light Source COB Light Line) manufactured by SCHOTT as well and launched full-fledged sales of various light source devices manufactured by SCHOTT.

Moritex has been expanding its product and commodity lineup in order to respond speedily to diversification of users' needs. The addition of SCHOTT's light source devices to the lineup of products Moritex handles has enabled provision of machine vision systems that are more diverse than ever before.



Now Possible to Provide PGx Test Services Compliant with Pharmaceutical Development GLP Standards

-Completion of GLP Conformity Check on PGx Research Center-

Moritex has obtained an "A-rating" signifying that "there is no nonconforming item or item to be improved" in the GLP Conformity Check by the independent administrative institution Pharmaceuticals and Medical Devices Agency conducted on Pharmacogenomics (PGx) Research Center's GLP facilities. This enables Moritex to provide PGx test services compliant with pharmaceutical development GLP standards, making it possible to respond more than ever to users' needs for high reliability in test results.

The remarkable development of genomic analysis technology has revealed that there is a correlation between the efficacy of drugs and occurrence of side effects and gene polymorphism. The realm expected to apply such a correlation to pharmaceutical development and diagnosis is pharmacogenomic (PGx). PGx is expected to become a huge market in the future along with pharmaceutical development and practice of personal medicine providing treatment suited for each individual patient.

In the United States, the FDA has already issued the FDA Guidance for Industry "Pharmacogenomics Data Submission" in March 2005. It is recommended that PGx data be attached to pharmaceutical development and diagnostics and the market is largely expanding. In the wake of such a trend, the PGx market is starting to emerge in Japan, calling for increases in facilities that are capable of PGx testing compliant with pharmaceutical development GLP standards. Moritex had been engaged in activities toward GLP compliant PGx tests since approximately two years ago, and have completed the GLP Conformity Check as of April 25, 2008.

With the completion of the GLP Conformity Check, Moritex will make a full-fledged entry into the drug concentration measurement undertaking business, including toxicokinetics (TK) measurement for which high reliability is demanded. Moritex will also conduct establishment and validation of the measurement method of drugs and metabolites under the LC/MS/MS method, as well as implement drug concentration measurement of non-clinical test samples and clinical test samples in accordance with GLP. The Company will also provide calculation and simulation services for pharmacokinetics parameters.

Moritex will take the completion of the GLP Conformity Check on the PGx Research Center as a chance to contribute to personal medicine by providing PGx test services with high reliability ensured.

Corporate Profile (as of March 31, 2008)

Corporate Name	Moritex Corporation
Headquarters	3-1-14, Jingu-mae, Shibuya-ku, Tokyo
Established	February 1973
Capital	3,320 million yen
Number of Employees	454
Business Year	From April 1 through March 31 of the following year
Major Affiliated Banks	Mizuho Corporate Bank, Ltd. Bank of Tokyo-Mitsubishi UFJ, Ltd. Sumitomo Mitsui Banking Corporation Resona Bank, Ltd.
Business Description	Manufacture, sales and export/import of machine vision systems, image equipment, optical communications-related equipment, bio-related business, functional commodities, optical equipment and related products and commodities

Offices

Headquarters	3-1-14 Jingu-Mae, Shibuya-ku, Tokyo, 150-0001 Japan Phone: 03-3401-9711 (Main)	North Kanto Branch	3-3-4 Arajuku-cho, Kawagoe City, Saitama Pref. 350-1124, Japan Phone: 049-247-2251
Tama Plaza Office	2-4-10 Shin-ishikawa, Aoba-ku, Yokohama 225-0003, Japan Phone: 045-914-3795	Nagoya Branch	2-2-17 Sakae, Naka-ku, Nagoya 460-0008, Japan Phone: 052-232-7871
Saitama Office	9-21-4 Tajima, Sakura-ku, Saitama, 338-0837 Japan Phone: 048-839-2550 (Main)	Kyoto Branch	3F NOA Takamatsuden Bldg, Anekoji-Agaru, Nishinotoin-dori, Nakagyo-ku, Kyoto 604-8277, Japan Phone: 075-223-3801
Yaita Office	1052-2 Nagamine, Naka Aza, Yaita City, Tochigi Pref. 329-2135, Japan Phone: 0287-43-5111 (Main)	Osaka Branch	ShinOsaka Doi Bldg, 7-5-25 Nishi-Nakajima, Yodogawa-ku, Osaka 532-0011, Japan Phone: 06-6838-8426
Yokohama Technical Center	1-3-3 Azamino-minami, Aoba-ku, Yokohama 225-0012, Japan Phone: 045-913-5800 (Main)	Fukuoka Branch	Maizuru Park Bldg., 1-4-30 Maizuru, Chuo-ku, Fukuoka 810-0073, Japan Phone: 092-733-3747
Tokyo Branch	3-1-14 Jingu-Mae, Shibuya-ku, Tokyo, 150-0001 Japan Phone: 03-3401-9756	Tochigi Sales Office	Hikari-machi U. Bldg., 1052-2, Nagamine, Naka Aza, Yaita City, Tochigi Pref. 329-2135, Japan Phone: 0287-43-1776
West Tokyo Branch	Olympic Tachikawa Bldg., 1-25-12 Akebono-cho, Tachikawa City, Tokyo 190-0012, Japan Phone: 042-548-1208	Hiroshima Sales Office	2-7-35 Hikari-Machi, Higashi-ku, Hiroshima City 732-0052, Japan Phone: 082-262-2542
Tsukuba Branch	Okano Jimusho, 1-21-8 Matusuro, Tsukuba City, Ibaraki Pref. 305-0035, Japan Phone: 029-852-1130	Tamagawa Distribution Center	4178-1 Oaza Tamagawa, Tokigawa-machi, Hiki-gun, Saitama Pref. 355-0342, Japan Phone: 0493-65-3616

Major Subsidiaries and Affiliates

Moritex U.S.A., Inc.	6862 Santa Teresa Blvd., San Jose, CA 95119 U.S.A. Established: February 1987 Capital: USD 700 thousand	408-363-2100 (Main) Representative: Tomohiro Mizuno, President
Moritex Europe Ltd.	14 Signet Court, Swanns Road, Cambridge CB5 8LA, U.K. Established: October 1989 Capital: GBP 877 thousand	01223-301148 (Main) Representative: John Parker, President
Moritex Hong Kong Co., Ltd.	77-87 Wang Lung Street Tsuen Wan, New Territories, Hong Kong Established: March 2000 Capital: HKD 24,000 thousand	2439-0968 (Main) Representative: Jiro Ishii, Chairman
Moritex Singapore PTE. LTD.	18 Boon Lay Way, #09-166, Tradehub 21, Singapore 609966 Established: November 2007 Capital: SGD 1,500 thousand	6515-9368 (Main) Representative: Akira Muramoto, President
Moritex Sales Corporation	3-10-5 Shibuya, Shibuya-ku, Tokyo 150-0002, Japan Established: March 2000 Capital: JPY 30 million	03-5766-6870 (Main) Representative: Masanobu Kimura, President
KOLC Inc.	2-4-10 Shin-ishikawa, Aoba-ku, Yokohama 225-0003, Japan Established: August 1997 Capital: JPY 30 million	045-914-3806 (Main) Representative: Kenji Itou, President
Moritex Precision Corporation	2-2-13 Ebisu, Shibuya-ku, Tokyo 150-0013, Japan Established: June 2003 Capital: JPY 60 million	03-5449-8177 (Main) Representative: Takayoshi Koguchi, President
Tohoku Moritex Corporation	1-5-21 Uesugi, Aoba-ku, Sendai 980-0011, Japan Zao Factory 1-224 Kawaramae, Aza, Magatake, Zao-machi, Established: January 1992 Capital: JPY 50 million	022-214-2771 (Main) Katta-gun, Miyagi, 989-0851, Japan 0224-33-3172 (Main) Representative: Tohru Ueda, President
Sensor Technology Co., Ltd.	4-9-17, Nakamachi, Atsugi City, Kanagawa 243-0018, Japan Established: November 1987 Capital: JPY 45 million	046-295-7061 (Main) Representative: Masumi Kawakami

(as of March 2008)